Molina Healthcare Inc (MOH) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, MOH scores 54 out of 100 with a letter grade of D+ and a verdict label of "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 10 of 20 (ROIC 17.2%; FCF yield -6.12%); Whale 13F Flow at 11 of 20 (institutional accumulation and options positioning); Insider Conviction at 9 of 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 10 of 20 (Beta 0.94; sector sensitivity); and Forensic Balance Sheet at 14 of 20 (Altman Z 4.34; Piotroski F 4/9; Debt/Equity 0.93). The strongest pillar is the forensic balance sheet, while the cash engine and macro fit pillars sit at half marks, and insider conviction is the weakest relative to its weight. For a prospective investor, the rating frames the stock as one where the reported return on invested capital is respectable but negative free cash flow yield and thin margins temper the case. Valuation metrics per the market data (P/E TTM 22, forward P/E 20.5) indicate the market is pricing in earnings recovery, a tradeoff the rating does not endorse. Upside drivers would need to come from margin repair and cash conversion; the rating's cautious verdict reflects that those improvements are not yet visible in the source data. This is an analytical summary, not personalized financial advice.

Per the market data, gross margin is 13.1%, operating margin 1.7%, and net margin 1%, with ROIC at 17.2%. Per the SEC financials, revenue rose from $34072.0M (FY 2023) to $45426.0M (FY 2025), while net income declined from $1179.0M (FY 2024) to $472.0M (FY 2025) and FCF moved to $-636.0M. Per the Roarable RQD rating, the Altman Z-Score is 4.34, the Piotroski F-Score is 4/9, and Debt/Equity is 0.93. Cash of $4248.0M against debt of $3766.0M is reported for FY 2025.

Per the recent news feed, five MOH items appear: a Yahoo Finance piece on the stock possibly trading at a discount despite reaffirmed 2026 guidance (YELLOW); a Forbes item (YELLOW); a Seeking Alpha piece characterizing the valuation as paying a premium for an unrealized recovery (YELLOW); a TradingView report that Q3 2026 sales topped estimates (YELLOW); and a Simply Wall St item on the stock looking reasonable relative to its sales base (YELLOW). A Yahoo Finance item flagged RED under RISK WATCH reports the stock dropping after Q3 results exposed a margin squeeze. The feed therefore contains mixed signals: a guidance reaffirmation and a sales beat alongside a margin-focused selloff. The Butterfly Supply-Chain Graph reports no supply chain links and no proprietary signals.

• What specific drivers account for the margin squeeze flagged in the Q3 news item, and how do they reconcile with the reaffirmed 2026 guidance?
• What is the composition of revenue and the medical cost trend behind the gap between FY 2024 and FY 2025 net income?
• Why is FY 2025 FCF negative, and is that expected to reverse?
• What is the EPS history, since reported EPS is N/A across all periods?
• Who are the institutional holders and insiders, and what is their recent activity?